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The Current Status of Hepatic Transplantation 
at the University of Pittsburgh 
Kareem Abu-Elmagd, John Fung, Satoru Todo, Abdul Rao, Jorge Reyes, 
g~ke Demetris, George Mazariegos, Paulo Fontes, John McMichael, 
Hlfo Furukawa, Forrest Dodson, Ashok Jain, Antonio Pinna, Wallis Marsh, 
fgn~zio Marino, Timothy Gayowski, Howard Doyle, Juan Madariaga, 
Adrian Casavilla, Robert Corry, Jorge Rakela, Shunzaburo Iwatsuki, and 
~·t 
Pi.ttsburgh Transplant, Departments o( Surgery, Medicine, and Pathology 
D,v,s,ons of Transplantation, University of Pittsburgh 
Pittsburgh, Pennsylvania 
During the last 7 years since February 1989. we have 
initiated 5 major developments in clinical transplantation. 
All have prominently (or in one instance exclusively) in-
volved the liver: (a) Clinical trials with the new immuno-
suppressive drug FK506 (tacroJimus); (b) Weaning of 
immunosuppressive drugs iong alter transplantation; (c) 
Enhancement of wnole organ allograft acceptance with 
adjuvant bone marrow infUSion; (d) Intestinal transplan-
tation. alone or as part of hepatic-intestinal and 
multivisceral allografts: and (e) Baboon-to-human liver 
xenotransplantatlon. The early results of these and other 
clinical studies were described in the 1993 and 1994 
editions of this bOOK. All of these clinical trials except 
xenotransplantatlon are still active. Here. we Will update 
the 4 active tnals and attempt to assess their future pros-
pects. 
The patient and graft survival curves for all studies 
were estimated by the Kaplan-Meier method and the 
comparisons were done by the log-rank test. Survival 
time for patients was defined as the time that elapsed 
from the transplantation date until death, or the date of 
the last follow-up evaluation. In calculating organ allograft 
survival, the date of death or the date of graft removal 
and retransplantation were considered the end points. 
Tacrolimus "FKS06" and Randomized 
Trialomania 
Fifteen years ago, the introduction of 
cyclosporine(CyA)/prednisone immunosuppression im-
proved the prognosIs of all organ recipients and elevated 
liver transplantation overnight to prac:ical and wloespread 
use (1). CyA-based regimens were unohallenged until a 
report appeared in late 1989 (2) describing a pilot clini-
cal experience with tacrolimus (FK506. Prograi®). The 
drug was first used clinically in replacement of CyA for 
liver recipients who were undergoing intractable graft 
relection. The remarkable 80% rescue rate in the first 
10 cases (2) always remained approximately the same 
as rescue trials expanded to hundredS of cases (3.4) 
and eventually to thousands, involving all kinds of al-
lografts. Beginning in August 1989, tacrolimus was given 
as the primary immunosuppressive drug from the time 
of hepatic replacement (2.5). 
Until these trials. kidney transplantation had been 
the whole organ procedure with which all new immuno-
suppressive agents and regimens had been developed 
(6-11). This precedent was broken with tacrolimus be-
cause its rescue role was so dramatic and so demon-
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Table 1. Patient characteristics of the Pittsburgh liver. transplant randomized trial. a 
CyA 
n (0/0) 
Number of patients 75 
Age (mean year) 42.5 
Sex (M/F) 46/29 
Indication for transplant 
Cirrhosis 
Alcoholic 21 (28) 
Post-hepatic 14 (19) 
Cryptogenic 9 (12) 
Cholestatic disease 
Primary biliary cirrhosis 8 (11 ) 
Primary sclerosing cholangitis 6 (8) 
Autoimmune hepatitis 5 (7) 
Biliary atresia 1 (1 ) 
Metabolic disorders 4 (5) 
Others 7 (9) 
Blood type 
A 41 (55) 
0 27 (36) 
B 4 (5) 
AB 3 (4) 
a Study terminated on May 30, 1995. 
strative from the outset of its superior therapeutic index. 
In November 1989. tacrolimus was placed onto the 'iast 
track" of the Unlied States Food and Drug Administra-
tion. Multicenter American (12) and European trials (13) 
were planned. comparing the use of tacrolimus and CyA 
as baseline agents from the time of transplantation. 
These began in August and September 1990. respec-
tively. By that time. more than 80 patients already had 
been enrolled in a prospective "single center". random-
ized trial which had begun in Pittsburgh in February 1990 
(14). The evidence of the superiority of tacrolimus for 
kidney (15) and thoracic organ (5,16) as well as liver (5) 
transplantation was overwhelming by the time of the 
Transplantation Society meeting in August 1990. Con-
sequently, all further randomized trials were conducted 
in the absence of equipoise (17.18). 
THE PITTSBURGH RANDOMIZED 
TRIAL 
Study Design 
All patients 16-60 years of age referred to the Uni-
versity of Pittsburgh for primary liver transplantation were 
considered to be potential candidates for randomization 
to CyA or tacrolimus (14). Exclusion criteria were: hepa-
FK506 CyA to FK506 CyAOnly 
n (%) n (%) n (%) 
79 47 28 
43.2 42.3 42.9 
49/30 26/21 20/8 
28 (35) 9 (19) 12 (43) 
17 (22) 10 (21) 4 (14) 
8 (10) 6 (13) 3 (11 ) 
8 (10) 6 (13) 2 (7) 
7 (9) 3 (6) 3 (11 ) 
2 (3) 4 (9) 1 (4) 
2 (2) 0 (0) 1 (4) 
2 (3) 4 (9) a (0) 
5 (6) 5 (11 ) 2 (7) 
29 (37) 23 (49) 18 (64) 
34 (43) 18 (38) 9 (32) 
11 (14) 4 (9) 0 (0) 
5 (6) 2 (4) 1 (4) 
titis B virus carrier state. cancer. need for multiorgan 
transplantation, renal insufficiency (creatinine >2 mgldl), 
active infection, stage 4 coma. significant cardiopulmo-
nary disease and prevIous hepatic hilar reconstructive 
or portal venous decompressive surgery. Four hours after 
revascularization of the liver allograft. it was determined 
if randomization should proceed or be aborted either 
because of a technically unsatisfactory operation or sub-
standard graft function. Treatment assignment with 
sealed-envelope implementation was determined with a 
computer-programmed block randomization technique 
to assure that the treatment groups remained reason-
ably balanced. No one was aware of the randomization 
status during the donor search, and up to the actual ran-
domization. The patient characteristics and indications 
for liver transplantation for each randomized arm are 
summarized in Table 1. 
Immunosuppressive Therapy 
Tacrollmus 
The drug was given by constant, 24-hour infusion at 
a starting dose of 0.1 mglkg/day. Intravenous treatment 
continued until oral administration could be started. The 
planned oral dose was 0.15 mg/1<g every 12 hours. The 
daily adjustments of the intravenous and. later. the oral 
doses of tacrolimus were guided by evidence of drug 
toxicity on one hand. graft rejection on the other. and the 
modifying influence of drug trough plasma levels which 
were targeted to 1-2 ng/ml (equivalent to whole blood 
levels of 10-20 ng/ml). Patients were not discharged 
from the hospital until oral doses were stable. at which 
time. the 12-hour plasma trough levels usually were 
around one ng/ml. With further longitudinal follow-ups, 
these plasma concentrations and the oral doses were 
allowed to drift down if rejection did not supervene, al-
ways taking into consideration drug toxicity and over im-
munosuppression versus control of rejection (18). 
Cyclosporine 
A comparable sliding scale strategy was used for 
CyA. beginning with a continuous infusion of 4 mg/kg/ 
day and optional oral starting doses of 8 mg/kg every 12 
hours which were overlapped with I.V. therapy. During 
the first few weeks. 12-hour whole blood trough concen-
trations were targeted to the 800-1500 ng/ml range. With 
further follow-ups. these concentrations were permitted 
to fall to 600-800 ng/ml if there was no evidence oi rejec-
tion. The similarity of side effects of eyA and tacrolimus, 
Pittsburgh Protocol 
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as well as the fact that dose adjustments were driven by 
the same 3 inter-related factors of rejection, toxicity and 
trough levels greatly facilitated management and out-
come comparisons! 
Prednisone 
In the first 81 recipients (CyA n=40; tacrolimus n=41), 
LV. methylprednisolone or oral prednisone was started 
at a daily dose of 20 mg/day (Fig. 1). Because of an 
overwhelming rate of treatment failure on the CyA arm 
with the low steroid doses. the protocol was unbalanced 
after case 81 by adding a 5-day LV. burst of prophylactic 
postoperative prednisone to the CyA (n=35) but not the 
tacrolimus arm (n=38). The bulge in prednisone dosage 
began with 200 mg on the first postoperative day fol-
lowed by 40 mg daily decrements until a maintenance 
level of 20 mg/day was reached on the sixth day. In 
addition. one gram of intravenous methylprednisolone 
was given intraoperatively to both cohorts. Reduction in 
the maintenance steroid doses was attempted in both 
arms in the absence of clinical or histopathologic evi-
dence of rejection. Several of the recipients. particularly 
those on the tacrolimus arm, were taken off prednisone 
at the end of the first postoperative month. 
Conditions for Crossover 
Ad hoc Dose 
AdJustments 
The diagnosis of liver rejection was 
suspected on the basis of clinical and bio-
chemical criteria. but required biopsy and 
histopathologic confirmation (18). In ad-
dition to these specifically Indicated bi-
opsies. protocol liver biopsies were ob-
tained before hospital discharge and in 
most cases at 2 months. Before going 
forward with biopsy. technical complica-
tions were always excluded by either a 
duplex scan. a cholangiogram or a he-
patic angiogram. as indicated. 
Figure 1. The experimental design of the Pittsburgh 
randomized trial. Treatment variables were equal 
except for the competing drugs. (eyA and 
tacrolimus) [From: Fung J. Eliasziw M. Todo S. et al. The 
Pittsburgh randomized trial of tacrolimus vs cyClosporine for liver 
transplantation. J Am Call Surg (in press)). 
Treatment failure was defined as the 
inability of the starting immunosuppres-
sion plus an orderly sequence of second-
ary therapy to control biopsy confirmed 
rejection (Fig. 2). The treatment of first-
time rejection consisted of a one gram 
bolus of prednisone which could be re-
peated once. if necessary, and followed 
in refractory cases by the 5-day burst of 
prednisone (200 mg/day with 40 mg dec-
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Algorithm for Rejection 
Rejection 
Baseline Drug + 'r 
20 mg/day --~F ) --+ ) 
Prednisone A 
1 gram Prednisone 
(plus 5-day cycle. 
if necessary) 
) 
,+. 
\ 
OKT3 
Course 
Statistical Analysis 
) 
~ 
Switch if 
unresolved 
Figure 2. Algorithm used to determine treatment 
failure, with the option of crossing over to the 
competing immunosuppressant drug. The diagnosis 
of rejection required biopsy proof. [From: Fung J, Eliasziw 
M, Todo S, et al. The Pittsburgh randomized trial of tacrolimus vs 
cyclosporine for liver transplantation. J Am Coli Surg (in press)]. 
A Cox proportional hazards regres-
sion modelling approach (19) was used 
to analyze the time-to-event data with 
treatment effects tested for statistical sig-
nificance using a likelihood ratio test. This 
approach allows for varying lengths of 
patient follow-up and is able to simulta-
neously control for the effect of patient 
baseline confounders on outcome. The 
endpOints for statistical analysis were 
freedom from biopsy-confirmed allograft 
rejection, retransplantation and death. 
Crossover was not considered to be an 
endpoint. The high early rate of unidi-
rectional crossover from CyA to 
tacrolimus made it impossible to specifi-
cally compare the spectrum of drug tox-
iCity of each treatment arm as an impor-
tant primary endpoint. 
RESULTS 
Patient Characteristics 
rements) and/or a 5-7 day course of OKT3. If these steps 
failed to control rejection, crossover from CyA to 
tacrolimus or vice versa was permitted. The reasons for 
crossover from CyA to tacroiimus are summarized in 
Table 2. Drug crossover was primarily dictated by treat-
ment failure. 
Table 2. The Pittsburgh liver transplant 
randomized trial and crossover from 
eyA to tacrolimus. 
Prior to Following 
Reject jon Rejection 
Reason for Crossover (n=7) (n=40) 
Steroid resistant rejection 0 26 
Refractory rejection 0 13 
CyA nephrotoxicity 0 1 
Ischemic injury 5 0 
Hemolysis 0 
Family insistence 0 
The 154 patients were recruited from February 16, 
1990 to December 26. 1991, with 79 patients random-
ized to the tacrolimus arm and 75 to CyA. The patient 
groups that emcrgl!!d from the intraoperative randomiza-
tion were Similar With respect to baseline characteristics 
(Table 1). No patients were lost to follow-up over the 
course of the study which terminated on May 3D, 1995. 
The mean duration of follow-up was 4 years. 
Drug Crossover 
A significant crossover from CyA to tacrolimus was 
triggered during the early postoperative months by the 
prospectively-defined treatment failure. This trend was 
observed even after induction prednisone was Increased 
disproportionately on the CyA limb during the second 
phase of the trial. After randomization, 47 of the 75 (63%) 
recipients assigned to eyA had been switched to 
tacrolimus. Seventy percent of these crossovers oc-
curred within the first month of randomization, with an-
other 28% crossing over during the rest of the first year 
of follow-up. Seven patients crossed over prior to rejec-
tion, whereas the other 40 switched to tacrolimus follow-
ing rejection (Table 2). The remaining 28 CyA patients 
remained in their assigned treatment arm for the dura-
tion of the trial, irrespective of intervening episodes of 
rejection or retransplantation. In contrast, only one re-
cipient who started on tacrolimus from the outset was 
changed to CyA. This occurred following 
retransplantation, preceded by an episode of rejection. 
Freedom from Rejection 
Cox regression analysis was performed using an 
indicator variable to represent treatment status and time 
to rejection as the outcome variable. The freedom from 
rejection curves (Fig. 3A) showed that patients random-
ized to the tacrolimus arm were less likely to have acute 
rejection than those receiving CyA (p=O.003. likelihood 
ratio test). The freedom from rejection at one year was 
36.2% for the tacrolimus patients and 16.8% for patients 
on CyA. The 95% confidence limits for the 19.4% differ-
ence in these rates were 6.9% and 31.9%. A subse-
quent analysis, which censored the 7 CyA patients (15%) 
who crossed over prior to an acute rejection (Table 2), 
yielded similar results. An analysis including age, sex 
and blood type. indications for transplant and starting 
dose of prednisone as covariates also produced similar 
results. 
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Exploratory Analyses 
The unique study design and pattem of crossovers 
influenced the framework for a set of exploratory analy-
ses. For these analyses, 3 groups were compared: the 
79 patients randomized to tacrolimus, the 47 patients 
who crossed over from CyA to tacrolimus, and the 28 
patients who remained in the CyA arm. The results of 
the comparisons discussed below must be interpreted 
cautiously since they were not protected by the random-
ization process. 
The baseline characteristics for these 3 groups are 
shown in Table 1. Figure 38 shows that the freedom 
from rejection curves for patients who crossed over from 
CyA to tacrolimus were identical to those for patients 
who did not cross over. This is reassuring, as the vast 
majority of crossovers from CyA to tacrolimus occurred 
after relection. There were no statistically significant dif-
ferences among the groups with regard to freedom from 
graft failure (Fig. 4, p=O.42), defined as a composite out-
come of retransplantation or death. When these out-
comes were considered separately, there was a striking 
difference in terms of freedom from retransplantation for 
patients receiving tacrolimus In comparison to those who 
3 Groups 38 
FK506 (n= 79) 
CyA to FK50S (n=47) 
CyA only (n=28) 
l"'--\ ----------
, 
~ 
--"-'-- --.-,--_ . ..--.---._-- ............ '---
5 0 2 3 4 5 
Y •• rofStudy 
Figure 3. A) Freedom from rejection (acute and chronic) comparing th~ 2 
randomized treatment arms. B) Freedom from rejection comparing patients 
randomized to tacrolimus with those randomized to eyA and subsequently crossed 
over with those who continued on eyA for the duration of the trial. [From: Fung J, Eliasziw 
M, Todo S, et al. The Pittsburgh randomized trial of tacrolimus vs cyclosporine for liver transplantation. J Am 
Call Surg (in press)]. 
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Figure 4. Freedom from 
retransplantation or death in the 
Pittsburgh randomized trial of 
tacrolimus versus CyA. [From: Fung J, 
Eliasziw M, Todo S, et al. The Pittsburgh 
randomized trial of tacrolimus vs cyclosporine for 
liver transplantation. J Am Coli Surg (in press)). 
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continued on CyA with a p value of 0.02 (Fig. 5). At 3 
years. freeaom from retransplantatJon for the tacrolimus 
patients was 90.3% compared to 70.7% for patients con-
tinuing on CyA. Finally, patient survival over the course 
of the tnal was virtually identical for all 3 groups of pa-
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Figure 6. Freedom from death in the 
Pittsburgh randomized trial of 
tacrolimus vs eyA. [From: Fung J, Eliasziw M, 
Todo S, et al. The Pittsburgh randomized trial of 
tacrolimus vs cyclosporine for liver transplantation. J 
Am Coli Surg (in press)). 
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Figure 5. Freedom from 
retransplantation in the Pittsburgh 
randomized trial of tacrolimus versus 
CyA. [From: Fung J, Eliasziw M, Todo S, et al. 
5 
The Pittsburgh randomized trial of tacrolimus vs 
cyclosporine for liver transplantation. J Am Coli Surg 
(in press)). 
tients (Fig. 6, p=O.95). At 3 years, patient survival was 
approximately U4°~ in each group. Reasons for 
retransplantation and causes of death are listed in Tables 
3 and 4, respectively. 
Adverse Events 
The adverse events included: central nervous sys-
tem, genitourinary, cardiovascular system, respiratory 
and gastrointestinal complications whether or not these 
were suspected of being adverse drug effects. A spec-
trum of complications that were not obviously related to 
drug therapy were also included: technical surgical acci-
dents, worsening of pre-existing cardiovascular disease, 
Table 3. The Pittsburgh liver transplant 
randomized study and retrans-
plantation. 
CyAto Reason for 
R.trans-
plantation 
Tacrollmus Tacrollmus CyA Only 
(n=8) (n=4) (n::8) 
Primary failure 1 0 4 
Ischemic injury 3 1 0 
Graft rejection 1 1 0 
Vascular 1 0 4 
Recurrent disease 2 0 
Infection 0 0 
Table 4. The Pittsburgh liver transplant 
randomized study: causes of death. 
CyAto 
Cause of 
Death 
Tacrollmus Tacrollmus CyA Only 
Infection 
Vascular 
Graft failure 
Multiorgan failure 
Respiratory failure 
Malignancy 
Recurrent liver 
disease 
(n=16) (n=10) (n=5) 
n (%) n (0/0) n (0/0) 
8 (47) 5 (50) 2 (40) 
4 (24) 2 (20) 1 (20) 
1 (6) a (0) 1 (20) 
1 (6) 0 (0) 0 (0) 
(6) 0 (0) 0 (0) 
(6) a (0) 1 (20) 
a (0) 3 (30) a (0) 
degenerative disorders. and traumatic accidents. Two 
de novo malignancies developed. one in each treatment 
arm. A patient who died of a squamous cell carcinoma 
of the larynx after 4.4 years always was on eyA. A pa-
tient who always was on tacrolimus died after 2.3 years 
from a disseminated squamous cell carcinoma of the 
oropharynx. 
It had been learned before the trial began that 
tacrolimus relative to eyA was associated With similar 
nephrotoxicity (20.21). diabetogeniclty (22) and neuro-
toxicity (15); an eqUivalent or lower rate 01 Intection 
(5.15.23.24); a reduced cumulative prednisone need 
(5.15.25); a lower incidence of hypertension (5.15.20) 
and less hyperlipidemia (5.15); and an absence of cos-
metic changes (hirsutism. facial brutalization and gingi-
val hyperplasia), The high early rate of unidirectional 
crossover trom eyA to tacrolimus made It impossible to 
compare these parameters on the 2 limbs because. ulti-
mately. the comparison became one of tacrolimus ver-
sus tacrolimus. In addition. all of the main toxicities were 
strictly dose related and couid therefore be ratcneted up 
or down at Will. 
THE MULTICENTER LIVER 
TRANSPLANT TRIALS: T ACROLIMUS 
VERSUS CYCLOSPORINE 
Unlearned Lessons 
The comparison of tacrolimus with eyA in 2 
multicenter. randomized trials was a prerequisite of gov-
emment regulatory agencies before tacrolimus could be 
marketed in pharmacies. and then only for the specific 
indication of liver transplantation. By the time investiga-
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tors met ,in March 1990. in London and Bethesda. re-
spectively. to plan multicenter liver trials. the toxiCity pro-
file and clinical pharmacokinetics of tacrolimus had al-
ready been delineated and published from Pittsburgh. 
including valuable management lessons (20-22.24-27). 
It had been recognized at an early time that the first 
Pittsburgh recipients treated with tacrolimus had been 
overdosed. and one-third reduction of the starting doses 
(to 0.1 mg/kg/day) already was adopted by February 1990 
(21.26.28). This reduction did not prevent toxic drug 
plasma levels in a significant number of patients. and 
consequently. the I.V. induction dose was lowered fur-
ther in August 1991 to 0.05 mg/kglday. Even more im-
portantly. it had been learned that the elimination of 
tacrolimus is dependent to a greater extent on the status 
of liver functions (21.26). making it clear why flexible and 
individualized dosing was so critical. Irreversible com-
plications had been avoided by using the characteristic 
side effects from the first day of treatment to determine 
dose ceilings; the occurrence of gran rejection estab-
lished the floor (5.15.29). From these observations. the 
meaning of drug plasma levels was quickly deduced. 
allowing drug level momtonng to be explOited in subse-
quent cases. 
These management lessons were the same as those 
which previously had made the use of CyA practical (30). 
but they were not well understood by many of the partici-
pants in the multicenter trials. Three features of these 
trials presaged problems (17). First. although some of 
the investigators had used the drug for rescue therapy. 
no pilot experience was allowed uSing tacrolimus as the 
pnmary immunosuppressive agent trom the time of trans-
plantation. Second. on-site plasma trough level moni-
toring was not available. Although the whole blood trough 
drug levels (about 10 times that of plasma) were mea-
sured. the results were not available for several days 
after sampling. Consequently, dose adjustment decisions 
were delayed. Finally. the high starting doses. long since 
abandoned in Pittsburgh. were used. A predictable epi-
demic of toxiCity reports developed Within a few weeks 
after the beginning of the trial in August (12) and Sep-
tember (13) 1990. Formal dose revisions were not made 
until 30% and 18%. respectively, of the European and 
American tacrolimus case enrollment had occurred. The 
gap between the multicenter study starting doses and 
those in concurrent use in Pittsburgh never closed. even 
by trial's end (Fig. 7). 
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Figure 7. Statting intravenous doses used in 
Pittsburgh (solid line) and in the US and European 
multicenter trials (dotted line). Note that the I. V. 
induction dose was already reduced by one-third by 
the time the Pittsburgh randomized trial was begun 
in February 1990 and that this was still too high. 
different reasons on the 2 arms. Cross-
over away from tacrolimus occurred be-
cause of its toxicity at the dangerously 
high doses being used and crossover to-
ward it occurred because of the compara-
tive lack of eyA efficacy that was still evi-
dent despite combining the CyA with high 
doses of induction prednisone. 
European Trial Results 
The distorting roles of tacrolimus 
overdose and a high rate of toxiCity were 
clarified by separate analyses of the early 
(high dose) and late (reduced dose) 
phases of the European multicenter ran-
domized trial. The statistical analysis, 
based on the intent-to-treat approach, 
showed significantly greater freedom from 
acute, intractable and chronic rejections. 
There were a 5% better patient survival 
and a 5% higher graft survival in the 
tacroiimus arm (13). The survival advan-
tage was not statistically significant, but 
Study Design 
the authors noted that about 10% of the surviving grafts 
credited to CyA were borne by patients wno had been 
rescued with and remained permanently on tacrolimus. 
The protocols used in 
the multicenter tnals (Fig. 8) 
resulted In unbalanced 
therapeutic schedules. The 
eyA arm was uoloaded With 
twice the induction doses of 
prednisone In all 12 Ameri-
can centers. a third drug 
(azathioprine) in 11 centers. 
and a fou rth agent 
(polyclonal ALG) in one. The 
8 European centers also had 
similar unbalanced and di-
verse protocols. On both 
sides of the Atlantic. CyA 
dose selection and adjust-
ment were at the physician'S 
discretion, whereas the high 
starting doses of tacrolimus 
were obligatory. The experi-
mental design resulted in fre-
quent drug switching, but for 
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Figure 8. "Unbalanced" experimental design in multicenter 
trials (American details shown). 
n = number of centers (From: Starz! TE, Donner A, Eliasziw M. et al. 
Randomized trialomania? The multicenter liver transplant trials of tacrolimus. 
Lancet, 1995; 346:1346). 
Table 5. Reasons for withdrawal 
(censoring) from American mi!lt!c~nter 
study for secondary end point analysis. a 
Tacrollmus CyA 
n (%) n (%) 
Total number 
randomized 
Total censored 
Reason for censoring 
263 
83 (31.6) 
Death 14 (5.3) 
2nd transplantation for 
technical problems 17 (6.5) 
Adverse event 37 (14.1) 
Lack of efficacy 6 (2.3) 
Administrativeb 9 (3.4) 
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102 (38.3) 
16 (6.0) 
21 (7.9) 
13 (4.9) 
32 (12.0) 
20 (7.5) 
a From Table 3: a comparison of tacrolimus (FKS06) and 
cyclosporine tor immunosuppression in liver transplanta-
tion. N Engl J Med 1994; 331:1110-111S. 
b Explanation (loss to follow-up. declination of further 
study. and failure to meet candidacy criteria after 
transplantation) not compatible with text. 
American Trial Results 
Critique of Report 
The publisned analysIs (12) left the impression, con-
trary to the European results (13) and our own experi-
ence (14.15), that the gain of better tacrolimus efficacy 
was essentially balanced by its higher toxicity. Critical 
examination of the original database (17) showed that 
analytic errors had led to this conclusion. Although the 
published American analysis (12) was claimed to be 
according to intent to treat. the data of 155 recipients 
who lived throughout the year, but were withdrawn from 
the trial analysis at various times and for different rea-
sons had their data censored for all stipulated end pOints 
except patient and graft survival: rejection, intractable 
rejection. need for retransplantation. steroid need and 
OKT3 use (Table 5). Thus. the only analyses done by 
intent-to-treat were patient and graft survival. 
In addition to the systematic violations of the intent-
to-treat principle. the inappropriate use of the Kaplan-
Meier method further eroded the validity of secondary 
end-point analysis in the American report (12). Instead 
of using the actual data generated by the patients who 
survived through the study period, end points subject to 
censoring were projected thereafter by Kaplan-Meier cal-
culations. An assumption underlying this calculation is 
that censoring is random with respect to treatment as-
signment (31). In the published analysis (12), both the 
number of recipients censored (102 CyA and 83 
153 
tacrolimus) and most of the reasons for censoring were 
distributed among both treatment arms in a non-random 
fashion (Table 5). While censoring due to adverse events 
was common in the tacrolimus arm, lack of efficacy and 
"administrative reasons" were more frequent causes of 
censoring in the CyA arm. 
According to the published data. the death (n:64) 
and retransplantation (n=52) rates were similar in both 
treatment arms and nearly equally contributed to the pri-
mary end-point results of patient and graft survival (12). 
However, a portion of patients in both categories were 
censored in the analysis of secondary end points, as 
previously mentioned. The listing of only 30 in the "cen-
sored by death" category meant that data following with-
drawal but preceding death had been omitted from sec-
ondary end-point analysis in the other 34 fatal cases. 
Also, the association of drug treatment with reduction of 
the retransplantation rate was obscured by the fact that 
38 of the 52 second engraftments were ascribed to "tech-
nical failures" and censored. In fact, grafts rescued by 
tacrolimus accounted for 20 (9.5%) of the 210 surviving 
grafts credited to the CyA arms at the end of the year. 
Reanalysis of the American Trial 
,he conventional intent-to-treat reanalYSIS was done 
with the original database (17). With respect to all im-
portant prognostic factors. randomization produced 
groups that were comparable at the outset. Using the 
"freedom from" formulation of the published study, the 
numerical results and their statistical significance were 
different than those published for all end points except 
for the one-year patient (88%) and graft (80.5%) sur-
vival. Consequently, stepwise restoration of all the cen-
sored subsets (shown in Table 5 from the published 
American account) (12) was required. 
With reanalysis, freedom from rejection as a single 
end point was accomplished in 39% versus 32% of the 
patients randomized to tacrolimus and CyA, respectively 
(p=0.025) (Fig. 9. left). When data was progressively 
reinserted from the different categories of censored pa-
tients, the "freedom from" curves of both arms progres-
sively descended (Fig. 9). Importantly, the extent of 
tacrolimus therapeutic advantage was maintained 
throughout with significant log-rank p values. It was note-
worthy in the reanalysis that restoration of freedom from 
adverse events had no effect on the tacrolimus superi-
ority present before this restoration. This unequivocally 
corrected the impression left by the published report that 
the greater tacrolimus efficacy was balanced by increased 
toxicity. 
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to 30 years postoperatively 
in the peripheral tissues or 
blood of human kidney, liver 
and thoracic organ recipi-
ents (34-39) (Fig. 11. A). 
When small numbers of 
donor cells were found us-
ing sensitive immunocy-
tochemical and polymerase 
chain reaction (peR) tech-
niques. we postulated that 
they constituted one limb of 
mutually antagonistic but 
ultimately reciprocally at-
tenuated or abrogated host-
versus-graft (HVG) rejec-
tion and graft-versus-host 
(GVH) reactions (Fig. 12). 
The dispanties in outcome 
with bone marrow and or-
DAYS POST TRANSPlANT 
• logrank lest .. .. . .... T ACROLIMUS 
- CYCLOSPORINE 
Figure 9. Freedom from various undesirable end points using 
tacrolimus versus eyA in reanalysis of American trial (log-rank 
test). (From: Starzl TE. Donner A, Eliasziw M. et al. Randomized trialomania? 
The multicenter liver transplant trials of tacrolimus. Lancet, 1995; 346:1346). 
The most clinically relevant results of the reanalysis 
are shown in Figure 10. By the end of the first postop-
erative year. 98% of the tacrolimus-randomlzed patients 
gan transplantation (Table 
6) could be explained by disruption of the leukocyte in-
teraction by the host cytoablation in the first instance. 
but not the second. 
were still free of refractory rejection ver- .-------------------------., 
sus only 87% in the CyA arm. Also, the 
composite freedom from the 3 factors that 
haunt transplant recIpients (refractory re-
jection, retransplar.tation and death) was 
80% for tacrolimus and 70% for CyA With 
P value of 0.008. 
DRUG-FREE GRAFT 
ACCEPTANCE 
The 2-Way Paradigm 
The modern era of transplantation 
usually is dated from the demonstration 
of Billingham. Brent and Medawar (32,33) 
of acquired tolerance in mice after their 
engraftment with adult allogeneic 
hematolymphopoletic cells during uterine 
or neonatal life. The connection between 
the consequent chimerism in these ani-
mals and the successful engraftment of 
whole organs was not apparent until the 
demonstration of persistent donor leuko-
FREEDOM FROM 
1.0 ~-K----- __________ K~h 
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• IOgrank lest 
.......... TACROLIMUS 
--- CYCLOSPORINE 
Figure 10. Freedom from refractory rejection (left), 
and refractory rejection plus graft loss (right)(from 
death or retransplantation) in reanalysis of American 
randomized trial. (From: Slarzl TE. Donner A. Eliasziw M, et al. 
Randomized trialomania? The multicenter liver transplant trials of 
tacrolimus. Lancet. 1995; 346:1346). 
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Figure 11. The mutual engagement of migratory immunocytes from the graft (A: 
organ, B: bone marrow) and the recipient under potent pharmacological 
immunosuppression '2-way paradigm". 
The canceling effect of the coexisting immunocyte 
populations in postoperatively immunosuppressed crgan 
recipients explained the poor prognostic discrimination 
or HLA matching In such cases, and the rarity of GVHD 
after transplantation of immunologically 
active organs. such as the intestine and 
liver (or both together). This also was 
postulated to be the reason for the char-
acteristic cycle of immunologic crisis and 
resolution (first observed in kidney recipi-
ents) (40) that are most commonly re-
flected by changes in graft function 
(Fig. 12). The suspicion that bone mar- Immune 
row and organ transplantation were mir- Reaction 
ror images, resulting from the drastically 
extramedullary bone marrow explains why immunosup-
pressive drugs can sometimes be stopped after human 
organ transplantation. especially when the organ is the 
liver (36,43). By October i 995, 12 (28%) of our 42 long-
Time after Transplantation 
different treatment strategies (Fig. 11). 
was strengthened by contemporary re-
ports describing a trace residual popula-
tion of recipient leukocytes in essentially 
all human bone marrow recipients who 
previously were thought to have complete 
donor cell chimerism (41 .42). 
Discontinuance of Drugs: 
Historical Experience 
The concept that successful organ 
transplantation involves, in essence. the 
engraftment of a fragment of donor 
Figure 12. Dualistic immune reactions of the HVG 
and GVH in the 2-way paradigm of transplantation 
immunology. The evolution of tolerance of each 
leukocyte population to the other is seen as a low-
grade stimulatory state that may wax and wane 
rather than a deletional one. 
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Table 6. Historical differences between bone 
marrow and organ transplantation. 
Bone Marrow Organ 
Yes 4- - RecIpient Cytoablation - -> No 
Critical <- - MHC compatibility - _ Not importantll 
GVHD 4- - Pnnclpal complication - -> Rejection 
Common «- - Drug-free state - _ Rare 
Tolerance 4- - Term for success - _ "Acceptance'b 
:; 
.Q 
E 
~ 
Z 
C 
.! 
';;j 
a.. 
Yes <- - Donor leukocyte chimerism-I> No 
a Except when certec! 
b "Operational tolerance' 
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Long Term Liver Transplant Survivors 
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Figure 13. Time of discontinuance of 
immunosuppressive therapy among 12 drug-free 
long-term liver transplant survivors (13.5-26 years). 
Table 7. Tolerance with infections. a 
PTLD HIV 
n 6 2 
Time drugs Meaian 1 year 6,7years 
stopped posttransolant (0.8 to 8 years) 
Survival rate \ 80°(0) 5/6 1/2 
Time drug free (years) 4.1 6.1 
Hev 
2 
0.5,2 years 
212 
4.2 
a This IS a fOllow-GD to Octoeer 1995, of a series reported to the 
Amencan Soc:etv of Transolant Surgeons in May 1993 (44). 
, est surviving liver recipients (13.5-26 
years) were drug free. The nearly equal 
cumulative duration of these 12 patients 
off immunosuppression and undertreat-
ment is evident in Figure 13. 
The foregoing collection does not 
include cases in which drugs were 
stopped because of life-threatening in-
fections. In May 1993. Reyes. et al (44). 
reported to the American Society of 
Transplant Surgeons that the 10 liver 
recipients shown in Table 7 had their im-
munosuppression stopped as early as 
6 months posttransplantation because 
of EBV-associated B-cell lymphomas, 
HIV or hepatitis C virus. After an aver-
age drug-free time of more than 4 years. 
8 (80%) of these 10 patients remain well. 
including 5 of the 6 with posttransplant 
Iymphoproliferative disease (PTlD). 
The Prospective Weaning 
Trial 
A prospective weaning triai begun 
in 1992 for liver rec:pients who were 5-
10 years posttranspiantation has 
complemented these observations (45). 
Candidates were limited to those who 
had been rejection free for at least 5 
years. A pre-weaning work-up includ-
ing baseline biopsy was necessary to 
rule out hepatitis or ongoing relection as 
well as occult complications of the al-
lograft vascular and biliary tract systems. 
Most of the patients entered (97%) 
had experienced one or more of the long-
term adverse effects of one or more of 
their immunosuppressive drugs, includ-
ing impending renal failure (24/80), skin 
cancer, verruca vulgaris of skin, signifi-
cant osteoporosis and arthropathy 
(n=12), morbid obesity (n=3). refractory 
systemic hypertension (25/80) and re-
current opportunistic infections. Wean-
ing gradually was done in 2 controlled 
steps; first. gradual reduction of the daily 
steroid doses with total withdrawal 
guided by the results of the corticotropin 
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University of Pittsburgh Medical Center 
Prospective Weaning Trial Results (n=80) 
safely. In 3 more, panic by the referring 
physiCian foreclosed the weaning. Other 
patients had weaning frozen when they 
were discovered to have biliary tract com-
plications, pregnancy, recurrent PSC, or 
recidivism of alcoholism after weaning 
had started. The overall impreSSion was 
that the vast majority of these patients had 
been arbitrarily kept at a level of immu-
nosuppression that they no longer 
needed. In the total collection of 80 
cases, including those who flunked wean-
ing, the ultimate daily doses of CyA and 
prednisone were essentially reduced by 
half, and the azathioprine doses even 
more so (Fig. 15). 
Rejection 
n_24 (30%) 
Off Drugs 29 ± 20 Months 
n=22 (27.5%) 
M.an W.aning Duration 
1.5 V .. r. 
Ongoing Weaning 
n=22 (27.5%) • unreliable 'ollowup = 4 physician paniC'" 3 
biliary tract patholOgy '" 2 
PBC recurrence = 1 
M •• n Duration 25 t 12 Month. 
renal 'allufe = 1 
Sleatohepauus = 1 
Figure 14. Update of the outcome analysis of the 
Pittsburgh prospective weaning trial results. (n=80) 
The Threat of Rejection 
The benefits of weaning are too ob-
stimulation test and second. gradual stepwise withdrawal 
of azathioprine. eyA or tacrolimus. Further reductions in 
immunosuppressIon were made on a monthly basis and 
biochemical monitonng of liver cell injury was done ev-
ery 1·2 weeks and when it was clinically indicated. Spe-
cific details of the weaning protocol and management 
policy have been published elsewhere (45). 
Rate of Success 
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c 
100 CD 
CI 
CD 
Gi 50 
> 
-< 
0 
vious to dwell upon. However. it is important to empha-
size that there was a 30% risk of histopathologically veri-
fied rejection (n=24). The rejections occurred from 1-29 
months after starting the weaning. Of interest. 4 rejec-
tions were in patients known from pnor study to have 
microchimerism. The rejections were classed 
histopathologically as minimal to mild in 20 cases ne-
cessitating only restoration of the previous baseline treat-
ment. However. the rejection was moderate or severe in 
Current Immunosuppression Decrease 
in Weaning Group 
8 l • Baseline Dosage 
IZI Cutrent Oosage 
6 -; 
4 
2 
CyA Azathioprine Prednisone 
In the first 80 cases. 44 (55%) of the 
starting patients have come off drugs 
completely or have moved uninterruptedly 
in that direction. Twenty-two (28%) have 
been completely off drugs for an average 
of 2.5 years (Fig. 14, right upper quad· 
rant). Weaning of these recipients was 
accomplished over 18 months. at a rate 
which we now believe was too fast. An-
other 22 patients are still weaning over a 
period of 2 years (Fig. 14. right lower 
quadrant). The slower weaning approach 
was prompted by a 30% inCidence of re-
jection (Fig. 14. left lower quadrant), in-
volving 24 patients to be discussed fur-
ther below. The final 15% (n=12) had 
weaning frozen at a lower than starting 
level for a vanety of reasons. In 4 of these 
cases, medical surveillance could not be 
maintained closely enough to proceed 
Figure 15. The current reduction in the baseline 
immunosuppressive dosage among the weaning 
liver recipient group. 
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Figure 16. The clinical course of the liver recipient 
who failed the immunosuppressive weaning trial. 
Note the sudden increase in serum bilirubin 28 
months post-wean which returned to normal value 
after rescue with low-dose tacrolimus. 
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Figure 17. The results of the Pittsburgh weaning trial 
according to the baseline immunosuppression. Note 
the better success with tacrolimus and azathioprine/ 
prednisone. 
4 cases and one of these patients be-
came jaundiced with a peak serum bi-
lirubin of 12 mgldl. All 4 were rescued 
by switching to tacrolimus. 
The clinical course of the liver re-
cipient with the worst rejection. and the 
only example of jaundice is shown in 
Figure 16. Another patient whose kid-
neys were failing from CyA toxicity had 
this drug abruptly stopped. 
Azathioprine and prednisone also were 
stopped much too quickly. However. the 
patient did well without drugs for almost 
2.5 years before developing acute re-
jection. After rescue with low-dose 
tacrolimus. liver function returned to 
normal over several weeks. He was 
started on renal dialysis and is waiting 
for a cadaver kidney. 
The circumstances in this case 
were Similar to those in a very unsatis-
factory weaning trial involving 12 pa· 
tients at the Mayo Clinic (46). Uke our 
patients. the Mayo recIpients were on 
tnple-drug therapy from whIch they were 
weaned rapidly because of CyA-asso-
ciated renal failure. The Mayo patients 
also were earlier in their course. only 
3.1 years posttransplantation, and prior 
stability of hepatic graft function was re-
quired for only one year. Six of the 12 
patients developed rejection, and 2 of 
the 6 died. 
Our earlier (45) and expanded 
weaning experience as well as that from 
the Mayo Clinic (46) has suggested that 
patients coming off complex CyA-based 
regimens have a high incidence of re-
jection. When our patients were on any 
of the CyA-based cocktails shown in 
Figure 17. they either could not be 
weaned or had a very low success rate. 
However, when monotherapy with CyA 
preceded weaning, the success rate 
rose to over 30%. Successful weaning 
was achieved regularly only in the pa-
tients being weaned from an 
azathioprine-prednisone regimen or 
from tacrolimus. 
DONOR LEUKOCYTE AUGMENTATION 
Donor leukocyte infusion to facilitate organ allograft 
acceptance was initially an eagerly anticipated natural 
extension of the neonatal tolerance models of Billingham, 
Brent and Medawar (32,33). The momentum carrying 
organ and bone marrow transplantation on a common 
current was lost between 1959 and 1963 when the pre· 
paratory recipient cytoablation plus donor bone marrow 
caused lethal GVHD in the MHC-disparate, outbred, large 
animals used to test the strategy (47,48, reviewed in 49). 
In addition, donor leukocytes were shown !lQl to be nec· 
essary for successful human kidney transplantation us· 
ing either total body irradiation (50·52) or immunosup· 
pressive drugs (40,53). Because it was not suspected 
that the leukocytes contained in the organs were capable 
of engraftment. chimerism was seemingly irrelevant to 
an explanation of organ allograft acceptance. A sec-
ondary dogma evolved that cytoablation to "make mi· 
croenvironmental space" was a necessary condition for 
leukocyte engraftment (reviewed in 54) in spite of early 
(55,56) and recent evidence (57) to the contrary. 
A Historical Perspective 
Despite these incorrect assumptions, the strategy 
of adjuvant donor bone marrow for organ transplanta-
tion was never completely abandoned, largely because 
of its expenmentally grounded advocacy by Monaco, et 
al (58-61). In an extensive clinical trial of the Monaco 
protocol in which cryopreserved donor bone marrow cells 
were given 3 weeks after cadaveric kidney transplanta· 
tion under conventional concitions of continuous immu-
nosuppression, Barber, et al (62), detected PCR evidence 
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of donor DNA in the blood of many of these patients. 
However, the same finding in some of the non-marrow 
controls aroused suspicion that this was an artifact until 
the discovery in 1992 of spontaneous chimerism (34-
38). Late follow-up studies of Barber's patients confirmed 
the presence of chimerism in both control and study pa-
tients, but far more frequently in the augmented cohort 
in which the long-term results were better (63). In addi· 
tion, sporadic reports (summarized in 64) of the benefit 
of donor-specific blood transfusion, first reported by 
Salvatierra, et al (65), prompted van Twuyver, et al (66), 
to speculate that transfusions (either donor-specific or 
from haplotype-matched, third party donors) could be 
causing stem cell engraftment and persistent 
microchimerism. 
The Pittsburgh Bone Marrow Trial 
When it was realized that these leukocyte augmen-
tation procedures were, in effect, iatrogenic amplifica-
tions of a natural posttransplant event (see prevIous sec-
tion), we began a prospective clinical trial in December 
1992 to enhance chimerism by perioperative infUSion of 
3-6 x 108/kg unmodified donor bone marrow (BM) cells 
in cadaveriC liver. kidney, and thoraCIC organ recipients 
(67). The trial was subsequently expanded to include 
whole pancreas and intestine. Conventional tacrolimusl 
prednisone immunosuppression was given, without any 
kind of recipient preconditioning. 
Global Results 
Table 8 summanzes the current status (to February 
1, 1996) of the first 150 patients treated between De-
cember 1992 and November 1995, compared With 95 
Table 8. Patient and graft survival in 8M-augmented and control primary organ 
allograft recipients. 
BM·Augmented Controls 
Survival (n) Survival (n) 
Organs Transplanted n Patient 
Liver 44 41 
Kidney 64a 64 
Heart 15 12 
Lung 15 12 
Small bowel 9c 7 
Multiorgan 3- 3 
Total 150 139 
• Kidney alone (n-32): +oancreas (n::25): +islets (n::7) 
Kidney alone (n=17); +pancreas (n=l7); +islets (n=2) 
C Small bowel alone (n=4): ... Iiver (n=3): +pancreas (n-2) 
Graft n Patient 
41 29 25 
59 36° 34 
12 18 17 
12 9 8 
6 3d 2 
3 0 0 
133 95 86 
d Small bowel alone (n=2); +Iiver (n=l) 
• Heart+lung (n=2); liver+kidney (n=l) 
Graft 
25 
33 
17 
8 
2 
0 
85 
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detectable by flow cytometric 
analysis (Fig. 19) and/or PCR in 
117 of 121 (97%) of the 
evaluable 8M-augmented pa-
tients compared to 36 of 73 
(49.5%) of the controls. The 
level of chimerism has been es-
timated to be greater than 1000 
fold that of control patients 
(67,68). Its multilineage char-
acter was confirmed in selected 
patients of the 8M group by de-
tection of donor DNA in the 
sorted T (CD3+). 8 (CD14+) and 
NK (CD5S+) cells in both myeloid 
and erythroid colonies. The 
presence of donor dendritic cell 
progenitors was demonstrated 
in GM-CSF and IL-4-enriched 
Figure 18. The cumulative risk of acute cellular allograft 
rejection among the 8M-augmented and control groups. 
contemporaneous control cases in which permission for 
8M harvest could not be obtained. 8M infusions did not 
cause complications. Trivial skin manifestations of GVHD 
similar to those which occur at about a 5% incidence 
atter conventional liver transolantations (36) were seen 
in 2 of the augmented liver recipients. These resolved 
spontaneously in one case and after a temporary in-
crease in prednisone dose In the other. it was notewor-
thy that none of the 8M-augmented intestinal or 
multivisceral recipients developed any evidence of 
GVHD. 
The high patient (92.7%) and graft survival (88.6%) 
was similar to that in the control cases (90.5% and 
89.5%). All of the surviving recipients still receive 
tacrolimus, but 40% of the study and 36% of control pa-
tients have had prednisone stopped. The nearly identi-
cal cumulative inCidence of rejection in the 2 groups is 
shown in Figure 18. Of interest, serial immunological 
monitoring revealed a 48% inCidence of induction of 
stable donor-specific hypo reactivity in evaluable study 
patients as compared to 32% of controls. In a study 
excluding patients with follow-up less than 6 months, 
donor-specific hypo reactivity was almost 2-fold higher in 
donor 8M-augmented liver, heart and lung transplant 
recipients than that in the control group. Of interest. this 
trend has not yet been seen in kidney recipients. 
While these parameters (including clinical course) 
have been similar in the 2 groups, peripheral blood mono-
nuclear cell (P8MC) chimerism has been consistently 
cultures of the PBMC. 
The foregoing results have conformed precisely to 
expectations engendered by the 2-way paradigm. The 
eventual effect of the greatly enhanced chimerism in the 
study group remains speculative. However, the cumula-
tive eVidence from a variety of rodent models (69-71) 
suggests that these recipients Will be selectively spared 
chronic rejection and can aspire to a drug-free state af-
ter a period of 5-1 0 years. 
The Liver Transplantation Results 
Forty-four of the 150 8M-augmented patients were 
primary liver reCipients. This subgroup is considered 
separately in Table 9. Although the differences in re-
sults versus the non-augmented controls are not yet sig-
nificant. the exceptionally high patient and graft survival 
and the 100% incidence of blood chimerism augers well 
for the future of these recipients. The 3 deaths in the 44 
reCipients were unrelated to marrow infusion. Two were 
caused by fulminant sepsis on postoperative day 22 in 
one case and on day 35 in the other. The third death 
was caused by metastatic recurrence of a malignant 
melanoma 18 months after transplantation. 
Three of the 44 augmented recipients were infants 
or children. The survivors of both study and control 
groups have excellent graft function (Table 9). About 
50% of liver recipients in each cohort are currently off 
steroids. With a minimum follow-up of one year, the cu-
mulative risk of rejection. the histopathologic grade of 
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Figure 19. Detection of donor (HLA-BW4+) cells in the PBMC of a BM-augmented 
liver recipient by flow cytometry. Density plot histogram suggests that at 883 days 
posttransplantation, 3.4% of lymphocytes within the recipient's circulation were of 
donor origin (D). A: Light scatter profile highlighting the gated events (in box); B: 
Isotype control for antibodies specific to donor HLA (lgG); C: Profile of cells stained 
with antibodies specific for the recipient HLA (B7). All analyses were performed on 
an EPIC Elite Flow Cytometer (Coulter Corporation, Hialeah, FL). 
rejection. and the response to treatment were similar in 
both groups (72). Immunological monitoring pertonned 
by MLR and supplemented by responses to mitogens 
and recall antigens revealed a 2-fold higher incidence of 
induction of donor-specific hypo-reactivity in study re-
cipients as compared to controls. 
This expenence indicates that adjuvant infusion of 
bone marrow for liver and other organ recipients is safe 
and that it augments the level of natural chimerism. Al-
though a trend towards more frequent development of 
stable donor-specific hypo-reactivity has been noted. it 
remains to be seen whether there will be better long-
tenn allograft survival and a reduced (or absent) need 
for immunosuppression. 
Table 9. Clinical features of BM-
augmented and control primary liver 
allograft recipients. 
BM-Augmented Control 
Number of patients 
Age (mean/year) 
Follow up (mean/months) 
Graft survival (%) 
Bilirubin (mean/mg/dl) 
Off steroids (%) 
ReJection (%) 
GVHD (%) 
Chimerism (%) 
44 
50:12 
17%8 
93 
0.7%0.5 
49 
43 
5a 
100 
29 
51:12 
22%3 
86 
0.7%0.3 
56 
56 
o 
50 
• Trivial skin rash requiring no treatment for one patient 
and small transient increase in prednisone for the other. 
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Table 10. Causes of intestinal failure 
and indications for liver-intestinal and 
multivisceral transplantation. 
Cause Liver-intestine Multlvisceral 
Adults (n=16) 
Crohn's disease 
Abdominal trauma 
Celiac A occlusion 
SMA thrombosis 
Desmoid tumor 
Metastatic gas!rinoma 
Budd-Chiari syndrome 
Pseudo-obstruction 
Children (n=30) 
GastroschisIs 
Necro-enterocolitis 
Volvulus 
Intestinal atresia 
Microvillus olsease 
Psudo-obstructlon 
Hirschsprungs disease 
1 
3 
0 
4 
1 
0 
0 
0 
8e 
6 
5 
4 
·2 
0 
1 
o 
o 
3-
o 
o 
o 
1 
1 
o 
2d 
o 
a These patients developed short-gut syndrome due to 
concomitant suoerlor mesenteric artery (SMA) 
thrombosIs because of protein S defcieney (n=l) 
anlithromDln 'II deficlenc'! (n=1) or unknown (n:1). 
b The Dallent received the multivlsceral graft after 
failure of :he :;nmary Isolate,) Intestinal graft due to 
refractory relectlon. 
C One patient reqlJired multivisceral retransplantation 
15 months arter receiving the liver·intestinal graft 
because of :;rart dysfunction. 
dOne callent -ad cseudo-obstruction after birth that 
was not diagnosed. and received isolated liver 
allograft 50 K~onths before the multivlsceral graft. 
LIVER-INTESTINAL AND ABDOMINAL 
MULTIVISCERAL TRANSPLANTATION 
Case Material 
During the period from July 24, 1990 until Septem-
ber 8. 1995. a consecutive senes of 46 patients were 
given liver allograrts In continUity With the intestine (n=35) 
or as part of a multivisceral composite graft (n=11). 
Tacrolimus immunosuppression was used in all cases 
(73-n). Thirty of these recipients were infants or chil-
dren with a mean age of 3.5 years (range. 0.5-15.5). The 
16 adults had a mean age of 32 years (range, 19-55). 
The indications for the 2 different transplant operations 
are shown in Table 10. In most cases. the liver failure 
was secondary to the cholestatic effect of long-term total 
parenteral nulntion (TPN). However. patients with liver-
based inborn errors of coagulation (see footnote a, Table 
10) or metas~tic hepatic disease tended to have better 
hepatic function. 
Three of the patients had previously undergone 
transplantation procedures. One of the multivisceral re-
cipients came to this operation after an isolated intesti-
nal allograft had been rejected (footnote b, Table 10); 
another had a prior liver/intestinal operation (footnote c, 
Table 10); and a third had undergone liver transplanta-
tion 50 months previously (footnote d, Table 10). The 
second of these 3 exceptional cases was left on the liver/ 
intestine list because this was the category that ac-
counted for almost all of the survival. 
Liver-Intestinal Graft Recipients 
All 35 of these recipients (9 adults and 26 children) 
had irreversible intestinal and hepatic failure. The 
Iymphocytotoxic crossmatch was positive in 3 recipients. 
One is still alive at 19 months. The other 2 died of chronic 
rejection and PTLD at 24 and 30 months after transplan-
tation, respectively. The colon was included in 9 of the 
35 liver/intestinal grafts shown in Table 10. and in one 
pediatriC patient with Hirschsprung's disease, it was used 
for rectal reconstruction by a Dull-through technique. 
Fourteen of the 35 allografts were obtained from cytome-
galovirus (CMV)-seropositive donors. 
Mult/visceral ReCipients 
There were 7 adults and 4 children (Table 10), ex-
cluding the one accounted for in footnote c. Although 
combined liver and Intestine grafting was initially con-
Sidered for most of these 11 patients. multivisceral trans-
plantation was chosen at the time of surgery because of 
a significantly ischemiC or diseased native stomach and! 
or pancreas. In one patient with Budd-Chiari syndrome 
and mesenteric venous thrombosis, fatal hemorrhage 
caused by portal hypertension was prevented during the 
multivisceral operation by temporarily occluding the ce-
liac axis and the superior mesenteric artery With intra-
aortic balloons placed under radiographic guidance 
preoperatively. This recipient survived the operation with 
a blood loss of 26 units (n). In another pediatric patient 
who had renal insufficiency following a failed liver-intes-
tinal transplantation. both kidneys were included enbloc 
with the multivisceral graft (77). A Iymphocytotoxic 
crossmatch was strongly positive in one patient who died 
of intractable cellular rejection after 58 days. The colon 
was part of the muitivisceral graft in 8 of the 11 recipi-
ents and 4 grafts were from CMV·seropositive donors. 
Donor Considerations 
All grafts were obtained from ABO blood type-iden-
tical cadaveric donors. HLA matching was random and 
uniformly poor. Immunomodulation of donors or grafts 
by either irradiation, antilymphocyte preparations (ALG, 
OKT3), or other modalities was studiously avoided. Rec-
ognition of the risks that this kind of manipulation intro-
duced, including the promotion of B-celllymphomas (78), 
was one of the key steps in bringing intestinal transplan-
tation to reality. The principles of composite graft har-
vesting have been described elsewhere (78). Modifica-
tions were frequently required to accommodate anatomic 
and pathologic circumstances in the recipient (73-79). 
In recent cases, BM cells have been removed from 
the donors for infusion into recipients of whole organs, 
including those containing intestine (see preceding sec-
tion). The dose of the unaltered BM cells was 3-6 x 108/ 
kg, given over 30-60 minutes, 2-12 hours after 
revascularization of the organ allograft. 
Postoperative Management 
The complex management of these unique recipi-
ents is described in detail elsewhere (80,81). Immuno-
suppression was the same as descnbed under the FK506 
trials for liver transplantation, using the high-dose ste-
roid induction. In a few cases, azathioprine or 
mycophenolate mofetil (RS61443, Cellceptl) was given 
as a third drug from the outset. In long-term survivors of 
the multivisceral operation, blood glucose and c-peptide 
levels were determined after Intravenous injection of 0.5 
glkg glucose. 
Intestinal graft relection was diagnosed by clinical 
findings. endoscopic examination and histopathological 
study of endoscopic-guided biopsies. Intestinal graft 
function was assessed by body weight, volume of stomal 
output, frequency and nature of the stools, and degree 
of dependency on TPN versus enteral feeding and/or 
oral diet. In addition. absorptive functions were directly 
measured by d-xylose tests and by 72-hour fecal fat ex-
cretion. Gastrointestinal motility was evaluated by mea-
surements of gastric emptying after radiolabeled test 
meals, intestinal transit time of a barium meal, and mano-
metric measures of contractile activity. 
Systemic antibiotics were given prophylactically for 
the first 5 days. as well as subsequently, if indicated by 
the results of blood and body fluid cultures. Selective 
gut decontamination was used for 4-6 weeks after trans-
plantation and resumed later during moderate to severe 
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rejection episodes. Chronic viral and protozoal prophy-
laxis was with acyclovir for CMV and bactrim for 
pneumocystis carinii. Because of the high incidence of 
CMV disease among most of the early recipients who 
received CMV-positive grafts, ganciclovir also was given 
prophylactically for 2-3 weeks in children and for 3 weeks 
to 3 months in adults based upon the CMV status of both 
donors and recipients. If severe CMV infection occurred 
despite prophylaxiS, Foscamet, CMV immunoglobulin or 
both. were added to or replaced the ganciclovir treat-
ment (82,83). 
Donor leukocytes circulating in the recipient periph-
eral venous blood were identified as donor with donor-
specific anti-HLA Class I monoclonal antibodies and by 
fluorescence-activated cell sorter analysis (67). The re-
sults were confirmed using probes directed against HLA 
Class II chromosomes by PCR and by in-situ hybridiza-
tion techniques With a Y-chromosome-specific probe. 
Survival 
Patients 
With potential follow-ups of 4-65 months (to Janu-
ary 1996), 25 (54%) of the 46 patients have died. The 
actuarial survival rates for the 2 types of transplantation 
combined (n=46) were 71 %, 65%, 52% and 41 % after 6, 
12. 24 and 60 months, respectively (Fig. 20A). There 
was no significant sUrlival difference with the 2 kinds of 
operations (Fig. 208). Survival was similar for adults 
and children (Fig. 21). Interestingly, there was no mor-
tality after 3 years among recipients who survived this 
long. 
The causes of the 25 deaths, (19/35 liver plus intes-
tine and 6111 multivisceral) were variable (Table 11). Fatal 
infections were responsible in 11 recipients. Graft rejec-
tion (n=5) or PTLD(n=5) accounted for 10 more. The 
remaining 4 patients died of technical (n=3) and man-
agement errors (n=1). 
Grafts 
Because all but 2 grafts were lost by patienfs death, 
the actuarial survival for the 48 grafts in the 46 patients 
closely mirrored patient survival (Fig. 22). Only 2 grafts 
(both liver/intestine) were removed and replaced at 
retransplantation - with another liver-intestinal graft in one 
case and a multivisceral graft in the other. Although the 
retransplant procedures were technically successful, the 
children died 60 and 57 days later from refractory rejec-
tion and PTLD, respectively. 
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Figure 20. The actuarial survival of the combined liver-intestinal and multivisceral 
recipients: A) ali 46 patients, and B) according to procedure. 
Two other recipients lost parts of their composite 
grafts. Severe preservation injury of the pancreas in one 
instance necessitated pancreatectomy. Hepatic artery 
thrombOSIS in the other allograft required replacement 
of the allograft liver (postoperative day 11). but the intes-
tine was spared. These patients died 197 and 29 days. 
respectively. after their primary transplantation. 
Risk Factor Analysis 
The practical and wide-
spread use of intestinal trans-
plant operations appeared from 
our early experience to be close 
at hand (73-75). Two correct-
able factors eroded these opti-
mistic expectations. One was 
inclusion of the colon with the 
small bowel (76.84) and the 
other was acceptance of the 
grafts from CMV-seropositive 
donors (76.82-84). 
- 80 ~ 
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en 50 
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CL. 30 
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10 
one year. 32% at 2 years and 26% at 3 years (p=O.04) 
(Fig. 23). The adverse effect of colon was more pro-
nounced in adults than in children. Increases in plasma 
tumor necrosis factor-alpha were higher in recipients 
given colon as opposed to those wno were not (76). This 
supported the pOSSibility that development of augmented 
endotoxemia in the c-olon recipients may have been a 
reason for the increased risk. 
..... Pediatric (n=30) 
.. Adult (n= 16) 
The C%n Question l~------------------------------------
The survival rate for grafts 
which did not include the colon 
(n=29) was 75%. 62% and 49% 
at one. 2 and 3 years. respec-
tively. Allografts that contained 
the colon had 42% survival at 
o 1 2 3 4 5 
Vears Posttransplant 
Figure 21. The actuarial patient survival after combined 
liver-intestinal and multivisceral transplantation among both 
adult and pediatric recipients. 
Table 11. Causes of death among liver-
intestinal and abdominal multivisceral 
recipients. 
Infection 
Viral 
Fungal 
Bacterial 
Rejection 
Acute 
Chronic 
8-cell 
lymphoma 
Technical 
Management 
erro,a 
Total 
(n=25) 
n (%) 
11 (44) 
5 
2 
4 
5 (20) 
4 
1 
5 (20) 
3 (12) 
(4) 
• Hypematremla. 
The CMV Factor 
Uver-Intestlnal Multlvisceral 
(n=19) (n=6) 
n (%) n (%) 
8 (27) 3 (50) 
3 2 
2 0 
3 1 
3 (16) 2 (33) 
2 2 
1 0 
4 (21) 1 (17) 
3 (16) o (0) 
1 (5) 0 (0) 
Recipients of CMV-positive liver-intestinal and 
multivisceral grafts (n=18) had 2- and 5-year survival 
rates of 40% and 20% compared to 60% and 52% when 
the donors were seronegative (n=28. p=O.03) (Fig. 24). 
Although the immediate cause of death often was some-
thing other than CMV. the pervasively harmful influence 
of the transplanted ViruS. and the necessity for its inten-
sive treatment, particularly in preoperatively CMV-nega-
tive recIpients. have been well documented (76.82.83). 
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Bone '!'farrow Augmentation 
We discussed earlier the insight about mechanisms 
of organ allograft acceptance that resulted from the dis-
covery of donor leukocyte microchimer-ism in long-sur-
viving organ recipients. Intestinal and multivisceral re-
cipients were initially excluded from the attempts in kid-
ney. liver and thoracic organ recipients to augment this 
spontaneous chimerism with donor 8M infusion. It was 
feared that adding 8M leukocytes to the immunologically 
active intestinal graft might push the recipient into GVHD. 
However. the absence of any significant complications 
after infusing 3-6 x 108lkg 8M cells in more than 100 
recipients of all of the other vital organs prompted us to 
extend this treatment to bowel recipients whenever per-
mission could be obtained from the donor family for BM 
removal. This was possible for 10 of the 15 intestinal 
transplantations performed during 1995 and up to De-
cember 31 (Table 12). 
The results in the 108M-augmented patients have 
been at least as good as in the 5 non-augmented con-
temporaneous controls (Table 12). The greatly aug-
mented chimensm IS construed to be an investment in 
the future of these patients. rather than a strategy to pre-
vent or control penoperative acute rejection. Of extreme 
importance. none of the 8M-augmented recipients de-
veloped any evidence of GVHD. 
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0 
0 1 2 3 4 5 
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Figure 22. Survival of the combined hepatic-intestinal and multivisceral grafts: A) all 
48 attempts including 2 retransplantation and B) according to procedure. 
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Figure 23. Survival of 19 primary grafts containing a colon 
segment versus 29 grafts not including colon (p=0.04). 
This experience has estab-
lished the feasibility, although not 
the practicality, of both combined 
liver-intestinal and multivisceral 
transplantation. Successfully 
treated patients had gratifying re-
habilitation with stable graft func-
tion for 5 years or longer in sev-
eral cases. Although gut absorp-
tion was never completely nor-
mal. 20 of the 21 current survi-
vors are free of intravenous nu-
tritional support. The exceptional 
patient (multivisceral) requires 
intermittent intravenous nutrition 
at night because of dysmotility 
of the gastrointestinal graft. Sev-
eral other patients take special 
dietary precautions to avoid di-
arrhea . 
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Figure 24. The detrimental effect of CMV-positive grafts on 
combined liver-intestinal and multivisceral patient survival 
These were the results in 
the pioneer era of 1990-1993 . 
After acquiring this experience. 
we declared a nearly one-year 
moratorium ,n order to develop 
strategies with which to circum-
vent the lethal nsk factors. The 
improved results in 1995 after 
resuming activity are eVident 
from Table 12. and have been 
particularly encouraging in the 
long view because of the safety 
of the 8M augmentation proto-
col. (p=0.0302). 
Table 12. Patient and graft survival in 8M-augmented and 
control intestinal allograft recipients. 
Isolated intestinal 
Combined liver-intestinal 
Multiviscerala 
8M-Augmented 
Survival (n) 
n Patient Graft 
5 
3 
2 
5 
1 
2 
4 
1 
2 
-liver, stomach, duodenum. pancreas, and intestine. 
2 
3 
o 
Control 
Survival (n) 
n Patient Graft 
1 
2 
o 
1 
2 
o 
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SUMMARY 
Tacrolimus is a more potent and satisfactory im-
munosuppressant than CyA for combination therapy 
with prednisone. In randomized trials comparing the 
2 drugs. the ability of tacrolimus to rescue intractably 
rejecting grafts on the competing CyA arm allowed 
equalization of patient and graft survival on both arms 
when the intent-to-treat analytic methodology was ap-
plied. The ability of tacrolimus to systematically res-
cue the treatment failures of CyA suggested, as a 
matter of common sense. that it is the preferred 
baseline drug for hepatic transplantation. This con-
clusion was supported by analysis of secondary end 
paints. including the ability to prevent rejection. 
Hepatic-intestinal. multivisceral and isolated in-
testinal transplantation became feasible on a practi-
cal baSIS only after the advent of tacrolimus. Never-
theless. better management strategies must be de-
vised before Intestinal transplantation, alone or with 
other abdominal viscera. Will meet its potential. One 
such strategy ;s based on the discovery of the pres-
ence of previously unsusoected. !ow-Ievel donor leu-
kocyte cnimensm In long-surviving allograft recipients. 
We believe that this chlmensm is the essential expla-
I, nation for :he feasibility of organ transplantation and a 
I link to the acaulred neonatal tolerance demonstrated by Billif1gham. Brent and Medawar (32). The 
II hematolymphoPoletic chimerism in organ recipients 
explains why weaning to a drug-free state in selected 
long-term survivors is frequently feasible and particu-
larly if the allograft is a liver. Weaning should never 
be attempted without a stepwise protocol and careful 
monitoring of graft function. 
Recognition of the natural chimerism that devel-
ops after whole organ transplantation has led to ef-
forts to augment it with perioperative donor BM infu-
sion. This procedure has been shown to be free of 
significant complications (including GVHD) in all kinds 
of whole organ recipients, including those given intes-
tine. 
The prospects of clinical xenotransplantation must 
be evaluated in the same context of chimensm as that 
delineated for allotransplantation with the discovery 
of spontaneous chimerism. Before addreSSing chi-
merism-related questions in xenotransplantation. the 
additional barner of the complement activation syn-
dromes that cause nyperacute rejection will have to 
be surmounted. Although measures to effectively 
transplant xenograrts have so far eluded us. the avall-
aOility of the more potent drug. tacrolimus, and recog-
nition of the seminal basis of allograft (or xenograft) 
acceptance via chimerism has inserted an element of 
reality Into the largely wishful thinl<.ing that has been 
evident in discussions about the future of 
xenotransplantation. 
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